{"title":"RSV immunization uptake among infants and pregnant persons — Wisconsin, October 1, 2023-March 31, 2024","authors":"Maddie Kemp, Ashley Capriola, Stephanie Schauer","doi":"10.1016/j.vaccine.2024.126674","DOIUrl":null,"url":null,"abstract":"<div><div>Respiratory syncytial virus (RSV) is the leading cause of hospitalizations among infants in the United States. New strategies to prevent RSV among infants and high-risk young children include the maternal RSVpreF vaccine (Abrysvo, Pfizer Inc.) and nirsevimab (Beyfortus, Sanofi and AstraZeneca), a long-acting monoclonal antibody. We examined immunization coverage among infants born during the 2023–24 RSV season and pregnant persons utilizing data from the Wisconsin Immunization Registry and Office of Vital Records to evaluate uptake of both products and overall infant protection against RSV. 5056 (18.2 %) infants received nirsevimab and 4767 (17.2 %) persons who gave birth during this timeframe received the maternal RSVpreF vaccine; 0.8 % of parent-infant dyads received both products. Overall, 36.2 % of infants were protected from RSV. These findings suggest that improved efforts on several fronts are needed to ensure equitable and timely access to both RSV products while also increasing the number of infants protected against RSV.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"47 ","pages":"Article 126674"},"PeriodicalIF":4.5000,"publicationDate":"2025-01-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vaccine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0264410X24013562","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Respiratory syncytial virus (RSV) is the leading cause of hospitalizations among infants in the United States. New strategies to prevent RSV among infants and high-risk young children include the maternal RSVpreF vaccine (Abrysvo, Pfizer Inc.) and nirsevimab (Beyfortus, Sanofi and AstraZeneca), a long-acting monoclonal antibody. We examined immunization coverage among infants born during the 2023–24 RSV season and pregnant persons utilizing data from the Wisconsin Immunization Registry and Office of Vital Records to evaluate uptake of both products and overall infant protection against RSV. 5056 (18.2 %) infants received nirsevimab and 4767 (17.2 %) persons who gave birth during this timeframe received the maternal RSVpreF vaccine; 0.8 % of parent-infant dyads received both products. Overall, 36.2 % of infants were protected from RSV. These findings suggest that improved efforts on several fronts are needed to ensure equitable and timely access to both RSV products while also increasing the number of infants protected against RSV.
期刊介绍：
Vaccine is unique in publishing the highest quality science across all disciplines relevant to the field of vaccinology - all original article submissions across basic and clinical research, vaccine manufacturing, history, public policy, behavioral science and ethics, social sciences, safety, and many other related areas are welcomed. The submission categories as given in the Guide for Authors indicate where we receive the most papers. Papers outside these major areas are also welcome and authors are encouraged to contact us with specific questions.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
